Multimodal prognosis of negative symptom severity in individuals at increased risk of developing psychosis.
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
24 05 2021
24 05 2021
Historique:
received:
13
10
2020
accepted:
30
04
2021
revised:
12
04
2021
entrez:
25
5
2021
pubmed:
26
5
2021
medline:
15
7
2021
Statut:
epublish
Résumé
Negative symptoms occur frequently in individuals at clinical high risk (CHR) for psychosis and contribute to functional impairments. The aim of this study was to predict negative symptom severity in CHR after 9 months. Predictive models either included baseline negative symptoms measured with the Structured Interview for Psychosis-Risk Syndromes (SIPS-N), whole-brain gyrification, or both to forecast negative symptoms of at least moderate severity in 94 CHR. We also conducted sequential risk stratification to stratify CHR into different risk groups based on the SIPS-N and gyrification model. Additionally, we assessed the models' ability to predict functional outcomes in CHR and their transdiagnostic generalizability to predict negative symptoms in 96 patients with recent-onset psychosis (ROP) and 97 patients with recent-onset depression (ROD). Baseline SIPS-N and gyrification predicted moderate/severe negative symptoms with significant balanced accuracies of 68 and 62%, while the combined model achieved 73% accuracy. Sequential risk stratification stratified CHR into a high (83%), medium (40-64%), and low (19%) risk group regarding their risk of having moderate/severe negative symptoms at 9 months follow-up. The baseline SIPS-N model was also able to predict social (61%), but not role functioning (59%) at above-chance accuracies, whereas the gyrification model achieved significant accuracies in predicting both social (76%) and role (74%) functioning in CHR. Finally, only the baseline SIPS-N model showed transdiagnostic generalization to ROP (63%). This study delivers a multimodal prognostic model to identify those CHR with a clinically relevant negative symptom severity and functional impairments, potentially requiring further therapeutic consideration.
Identifiants
pubmed: 34031362
doi: 10.1038/s41398-021-01409-4
pii: 10.1038/s41398-021-01409-4
pmc: PMC8144430
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
312Références
Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
Schizophr Bull. 2007 May;33(3):688-702
pubmed: 17440198
Psychiatry Investig. 2017 Sep;14(5):539-545
pubmed: 29042877
Curr Opin Psychiatry. 2017 May;30(3):209-219
pubmed: 28212173
Nat Neurosci. 2000 Jan;3(1):80-4
pubmed: 10607399
World Psychiatry. 2017 Jun;16(2):209-210
pubmed: 28498587
Front Psychiatry. 2019 Apr 24;10:216
pubmed: 31105596
Schizophr Bull. 2017 Oct 21;43(6):1190-1196
pubmed: 28981842
Annu Rev Clin Psychol. 2018 May 7;14:91-118
pubmed: 29401044
JAMA Psychiatry. 2018 Nov 1;75(11):1156-1172
pubmed: 30267047
J Abnorm Psychol. 1992 Feb;101(1):184-91
pubmed: 1537965
Schizophr Bull. 2017 Mar 1;43(2):375-388
pubmed: 27535081
Cereb Cortex. 2008 Oct;18(10):2352-7
pubmed: 18267953
Psychol Med. 2017 May;47(7):1163-1178
pubmed: 28091343
Schizophr Bull. 2014 Nov;40(6):1452-61
pubmed: 24550526
Brain. 2009 Mar;132(Pt 3):617-27
pubmed: 18971202
J Neural Transm (Vienna). 2015 Jan;122(1):155-69
pubmed: 25319445
Psychol Med. 2018 Apr;48(6):983-997
pubmed: 28874223
Schizophr Bull. 2018 Jun 6;44(4):807-823
pubmed: 29069511
JAMA. 2005 Nov 2;294(17):2221-4
pubmed: 16264165
Schizophr Res. 2014 Apr;154(1-3):100-6
pubmed: 24613572
Philos Trans R Soc Lond B Biol Sci. 2003 Mar 29;358(1431):459-73
pubmed: 12689373
Eur Psychiatry. 2015 Mar;30(3):405-16
pubmed: 25735810
J Abnorm Psychol. 2001 Aug;110(3):363-71
pubmed: 11502079
Neurosci Biobehav Rev. 2016 Jun;65:276-91
pubmed: 27073047
Psychiatry Res. 2012 Apr 30;196(2-3):220-4
pubmed: 22445704
Am J Psychiatry. 2003 Sep;160(9):1606-13
pubmed: 12944334
Philos Trans R Soc Lond B Biol Sci. 2003 Mar 29;358(1431):435-45
pubmed: 12689371
J Psychiatr Res. 2016 Oct;81:95-101
pubmed: 27424062
Neurosci Biobehav Rev. 2017 Aug;79:1-13
pubmed: 28501553
Schizophr Res. 2015 Dec;169(1-3):204-208
pubmed: 26530628
Schizophr Res. 2016 Jun;173(3):159-165
pubmed: 25819936
Schizophr Res. 2004 May 1;68(1):37-48
pubmed: 15037338
JAMA Psychiatry. 2013 Jan;70(1):107-20
pubmed: 23165428
Epidemiol Psychiatr Sci. 2011 Mar;20(1):45-54
pubmed: 21657115
Psychiatry Investig. 2010 Dec;7(4):257-63
pubmed: 21253409
Acta Psychiatr Scand. 2018 May;137(5):380-390
pubmed: 29532909
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
Lancet Psychiatry. 2015 May;2(5):403-412
pubmed: 26360284
Schizophr Bull. 2003;29(4):633-51
pubmed: 14989404
Neuron. 2011 Dec 8;72(5):873-84
pubmed: 22153381
JAMA Psychiatry. 2016 Mar;73(3):191-2
pubmed: 26765254
Schizophr Bull. 2019 Sep 11;45(5):1042-1050
pubmed: 30535399
Schizophr Res. 2017 Aug;186:29-38
pubmed: 27230288
Front Psychiatry. 2018 Sep 19;9:446
pubmed: 30283368
Annu Rev Psychol. 2011;62:103-34
pubmed: 21126178
Annu Rev Psychol. 2012;63:287-313
pubmed: 21838544
Psychol Med. 2020 Apr;50(6):936-947
pubmed: 30994080
Science. 2015 May 1;348(6234):499-500
pubmed: 25931539
Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Sep;3(9):798-808
pubmed: 29789268
J Neurosci. 2011 May 11;31(19):7174-7
pubmed: 21562281
World Psychiatry. 2018 Jun;17(2):133-142
pubmed: 29856558
Nature. 2009 Jul 9;460(7252):202-7
pubmed: 19587761
Nat Rev Neurosci. 2006 Dec;7(12):942-51
pubmed: 17115076
JAMA Psychiatry. 2018 Dec 1;75(12):1289-1297
pubmed: 30347013
Schizophr Bull. 2014 May;40(3):675-84
pubmed: 23615812
JAMA Psychiatry. 2018 Jun 1;75(6):613-622
pubmed: 29710118
Neuron. 2012 Jun 21;74(6):990-1004
pubmed: 22726830
Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Mar;3(3):223-230
pubmed: 29486863